In the present study, we have described in detail of some of the miRNAs or lncRNAs that can be used as therapeutic tools to alter the expression of ERCC1 and reverse back the cisplatin sensitivity in lung cancer cells. This evidence concerns the gene ERCC1 and lung carcinoma.